⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKBA News
Akebia Therapeutics, Inc.
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
globenewswire.com
AKBA
Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics
globenewswire.com
AKBA
GSK
VRTX
PFE
SNY
NVS
JNJ
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
globenewswire.com
AKBA
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Form 8-K
sec.gov
AKBA
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
globenewswire.com
AKBA
Braveheart Bio Appoints Emil deGoma, M.D., as Chief Medical Officer
prnewswire.com
AKBA
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
globenewswire.com
AKBA
Breath Analyzers Market worth $5.63 billion by 2031 | MarketsandMarkets™
prnewswire.com
LOCO
ABT
AKBA
BAC
CMII